GSK subsequently developed GSK2831781, its own depleting anti-LAG-3 antibody based on IMP731 which was humanized and was afucosylated for higher Antibody-dependent cellular cytotoxicity.
GSK subsequently developed GSK2831781-3 antibody based on IMP731. This IMP731 was humanized. GSK subsequently was afucosylated for higher Antibody-dependent cellular cytotoxicity. GSK2831781 was its own depleting anti-LAG.